Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1000

Benzinga Newsdesk www.benzinga.com Positive 79.3%

Neg 0% Neu 0% Pos 79.3%

Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $995 to $1000.